A Phase 2 interventional study of Gadopiclenol in Central Nervous System Diseases, Pediatric Disorder and Body Indication, sponsored by Guerbet. Completed at 11 sites in 3 countries. Open to participants aged Up to 23 Months. Per ClinicalTrials.gov, last updated 2025-10-28.
Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Central Nervous System Diseases with a site in Poland — 1 open to participants now, 3 under way, 2 of them phase 3. Central Nervous System Diseases · Poland.
Among the 22 studies in Central Nervous System Diseases with a site in Poland, this one is the 21st largest by enrollment, is one of 3 that started in 2022, is one of 7 in phase 2, and was the 19th registered.
386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.
Browse Central Nervous System Diseases studies →1 of the 22 studies in Central Nervous System Diseases with a site in Poland is open now. Recruiting first, the newest first:
MapLight Therapeutics · Sites in Poland, United States, Argentina and 12 more countries
Ages 55–90
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 75 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 21 (28%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: Up to 23 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 14
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 52 across 296 interventional studies indexed under Central Nervous System Diseases.
Median enrollment 286 across the 22 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 2 studies filed under Central Nervous System Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Central Nervous System Diseases with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach.
Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).
Three age groups are defined:
At study set-up, the inclusions started with the oldest patients in group 1 and using an age-down staggered approach.
The decision to start the inclusions in group 2 was taken by the Trial Safety Review Board based on safety assessment over one-day period after injection of the first 13 patients in group 1.
According to the protocol version 4 (amendments 2 \& 3), the age-down staggered approach was discontinued to allow the inclusions in Group 3 (patients aged from birth to 27 days), simultaneously to inclusions in group 1 and group 2.
A total of 3 blood samples per patient were taken post-injection for PK analysis.
Main Inclusion Criteria:
Main Exclusion Criteria:
9. Patient undergoing a change in chemotherapy (product or dosage) within one day prior to or one day after gadopiclenol administration, 10. Patient who received or will receive any other contrast agent for CT and/or MRI within one week prior to or one week after gadopiclenol administration, 11. Patient with for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker), 12. Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents [...]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
Drug: Gadopiclenol
One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
Drug: Gadopiclenol
One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
Drug: Gadopiclenol
Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
Also known as: Elucirem
Area Under the Curve (AUCinf)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours)
Elimination Half-life (t1/2α)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Terminal Half-life (t1/2β)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Gadopiclenol Concentrations 10 Min Post-injection (C10 Min)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: blood sample collection 10 minutes post-injection of gadopiclenol for analysis
Gadopiclenol Concentration 20 Min Post-injection (C20 Min)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: blood sample collection 20 minutes post-injection of gadopiclenol
Gadopiclenol Concentrations 30 Min Post-injection (C30 Min)
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
Time frame: blood sample collection 30 minutes post-injection of gadopiclenol
Clearance
Individual predicted final model parameter scaled by body weight
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Central Volume of Distribution (V1)
Individual predicted final model parameter scaled by body weight
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Inter-compartment Clearance (Q)
Individual predicted final model parameter scaled by body weight
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
Peripheral Volume of Distribution (V2)
Individual predicted final model parameter scaled by body weight
Time frame: A total of 3 blood samples per patient were collected post-injection of gadopiclenol for PK analysis, one within each window (10-60 minutes, 2-4 hours and 6-8 hours).
| Milestone | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Started | 33 | 2 | 1 |
| Completed | 32 | 2 | 1 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| h.mg/L | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Area Under the Curve (AUCinf) | 392.3 ± 27.6 | 493.3 ± 9.9 | — |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| h | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Elimination Half-life (t1/2α) | 0.3 ± 30.3 | 0.3 ± 30.3 | — |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| h | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Terminal Half-life (t1/2β) | 1.5 ± 21.4 | 2.1 ± 8.4 | — |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| mg/L | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Gadopiclenol Concentrations 10 Min Post-injection (C10 Min) | 226.8 ± 15.8 | 190.4 ± 16.2 | — |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| mg/L | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Gadopiclenol Concentration 20 Min Post-injection (C20 Min) | 161.5 ± 17.2 | 149.8 ± 13.4 | — |
Exposure parameter by age group predicted from the final model in participants with normal renal function receiving gadopiclenol at a dose of 0.05 mmol/kg
| mg/L | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Gadopiclenol Concentrations 30 Min Post-injection (C30 Min) | 109.4 ± 22.4 | 116.2 ± 13.3 | — |
Individual predicted final model parameter scaled by body weight
| L/h/kg | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Clearance | 0.128 ± 0.035 | 0.097 ± 0.004 | — |
Individual predicted final model parameter scaled by body weight
| L/kg | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Central Volume of Distribution (V1) | 0.176 ± 0.033 | 0.214 ± 0.03 | — |
Individual predicted final model parameter scaled by body weight
| L/h/kg | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Inter-compartment Clearance (Q) | 0.099 ± 0.025 | 0.123 ± 0.029 | — |
Individual predicted final model parameter scaled by body weight
| L/kg | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Peripheral Volume of Distribution (V2) | 0.066 ± 0.014 | 0.066 ± 0.003 | — |
Collected over Adverse events (AE) occurring from the beginning of patient's participation in the trial (Informed Consent Form signature) until the end of the participation (up to 3 months following gadopiclenol administration).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age Group 1: Patients Aged 3 to 23 Months | 0/33 (0%) | 8/33 (24.2%) | 13/33 (39.4%) |
| Age Group 2: Patients Aged 28 Days to Less Than 3 Months | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| Feeding DisorderMetabolism and nutrition disorders | 1/33 | 0/2 | 0/1 |
| Tumour ExcisionSurgical and medical procedures | 1/33 | 0/2 | 0/1 |
| PyrexiaGeneral disorders | 1/33 | 0/2 | 0/1 |
| Microcytic AnaemiaBlood and lymphatic system disorders | 1/33 | 0/2 | 0/1 |
| Gastroenteritis NorovirusInfections and infestations | 1/33 | 0/2 | 0/1 |
| Pneumonia Parainfluenzae ViralInfections and infestations | 1/33 | 0/2 | 0/1 |
| BronchitisInfections and infestations | 1/33 | 0/2 | 0/1 |
| Cerebral CystNervous system disorders | 1/33 | 0/2 | 0/1 |
| Intracranial Pressure IncreasedNervous system disorders | 1/33 | 0/2 | 0/1 |
| Device MalfunctionProduct Issues | 1/33 | 0/2 | 0/1 |
| Event | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) |
|---|---|---|---|
| HypertensionVascular disorders | 0/33 | 1/2 | 0/1 |
| Aspartate Aminotransferase IncreasedInvestigations | 0/33 | 1/2 | 0/1 |
| Serum Ferritin IncreasedInvestigations | 0/33 | 1/2 | 0/1 |
| VomitingGastrointestinal disorders | 5/33 | 0/2 | 0/1 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 1/33 | 0/2 | 0/1 |
| ConjunctivitisInfections and infestations | 1/33 | 0/2 | 0/1 |
| ParonychiaInfections and infestations | 1/33 | 0/2 | 0/1 |
| Hand-Foot-And-Mouth DiseaseInfections and infestations | 1/33 | 0/2 | 0/1 |
| AnxietyPsychiatric disorders | 1/33 | 0/2 | 0/1 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/33 | 0/2 | 0/1 |
Baseline analysis population included 36 patients who received one injection of gadopiclenol (safety set): 33 patients aged 3 to 23 months, 2 aged 28 days to less than 3 months and 1 patient aged 0-27 days.
| Age, Continuous(months) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| Mean | 13.11 ± 6.22 | 1.94 ± 0.14 | 0.8 ± NA | 12.15 ± 6.77 |
| Sex: Female, Male(Participants) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| Female | 17 | 1 | 0 | 18 |
| Male | 16 | 1 | 1 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 32 | 2 | 1 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 33 | 2 | 1 | 36 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| Hungary | 10 | 1 | 1 | 12 |
| United States | 4 | 1 | 0 | 5 |
| Poland | 19 | 0 | 0 | 19 |
| Weight(kilogram) | Age Group 1: Patients Aged 3 to 23 Months | Age Group 2: Patients Aged 28 Days to Less Than 3 Months | Age Group 3: Patients Aged From Birth to 27 Days (Term Newborns) | Total |
|---|---|---|---|---|
| Mean | 9.40 ± 2.18 | 5.10 ± 0.28 | 4.50 ± NA | 9.03 ± 2.44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Sep 2024, 24 months.
Results were first posted in Oct 2025, 1 year after primary completion.
Of 37 phase 2 interventional studies under Central Nervous System Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 44. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol
Central Nervous System Diseases →